Conduit Pharmaceuticals Enters Material Definitive Agreement
Ticker: CDTTW · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1896212
| Field | Detail |
|---|---|
| Company | Conduit Pharmaceuticals Inc. (CDTTW) |
| Form Type | 8-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $11.50, $800,000, $10, $80,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
Conduit Pharma just signed a big deal, creating new financial obligations. Details in the 8-K.
AI Summary
On October 9, 2024, Conduit Pharmaceuticals Inc. entered into a material definitive agreement. This agreement also creates a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. The filing includes financial statements and exhibits related to this event.
Why It Matters
This filing indicates a significant new contract or financial commitment for Conduit Pharmaceuticals, which could impact its future financial performance and operational strategy.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements and creating financial obligations can introduce new risks related to performance, financing, and market conditions.
Key Players & Entities
- Conduit Pharmaceuticals Inc. (company) — Registrant
- October 9, 2024 (date) — Date of earliest event reported
FAQ
What type of material definitive agreement did Conduit Pharmaceuticals Inc. enter into?
The filing states that Conduit Pharmaceuticals Inc. entered into a material definitive agreement, but the specific nature of the agreement is not detailed in the provided text.
What are the specific financial obligations created by this agreement?
The filing indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement, but the exact details of these obligations are not specified in the provided text.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on October 9, 2024.
What is the SEC file number for Conduit Pharmaceuticals Inc.'s filing?
The SEC file number for Conduit Pharmaceuticals Inc. is 001-41245.
What is the Central Index Key (CIK) for Conduit Pharmaceuticals Inc.?
The Central Index Key (CIK) for Conduit Pharmaceuticals Inc. is 0001896212.
Filing Stats: 854 words · 3 min read · ~3 pages · Grade level 11.5 · Accepted 2024-10-15 17:00:29
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CDT The Nasdaq
- $11.50 — of Common Stock at an exercise price of $11.50 CDTTW The Nasdaq Stock Market LLC
- $800,000 — urity Date") in the principal amount of $800,000 (the "Convertible Note"). The Convertib
- $10 — s into common stock at a fixed price of $10 per share. All accrued but unpaid inter
- $80,000 — Securities Act of 1933, as amended, (a) $80,000 worth of shares of the Company's common
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex10-1.htm (EX-10.1) — 37KB
- ex10-2.htm (EX-10.1) — 37KB
- ex10-2_001.jpg (GRAPHIC) — 7KB
- 0001493152-24-041154.txt ( ) — 369KB
- cdt-20241009.xsd (EX-101.SCH) — 4KB
- cdt-20241009_def.xml (EX-101.DEF) — 29KB
- cdt-20241009_lab.xml (EX-101.LAB) — 36KB
- cdt-20241009_pre.xml (EX-101.PRE) — 27KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 15, 2024 CONDUIT PHARMACEUTICALS INC. By: /s/ Dr. David Tapolczay Name: Dr. David Tapolczay Title: Chief Executive Officer